Suppr超能文献

美国和加拿大大麻消费者中四氢大麻酚和大麻二酚水平的相关知识。

Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.

作者信息

Hammond David, Goodman Samantha

机构信息

School of Public Health and Health Systems, University of Waterloo, Waterloo, Canada.

出版信息

Cannabis Cannabinoid Res. 2022 Jun;7(3):345-354. doi: 10.1089/can.2020.0092. Epub 2020 Oct 29.

Abstract

This study aimed to examine consumer knowledge of tetrahydrocannabinol (THC) and cannabidiol (CBD) levels for usual cannabis products. Data are from the International Cannabis Policy Study conducted online in August-September 2018. Respondents included 6471 past 12-month cannabis users, aged 16-65 years, recruited from the Nielsen Global Insights Consumer Panel using nonprobability methods. Respondents were recruited from Canada, which had not yet legalized nonmedical cannabis (=2354), and US states that had (=2160) and had not (=1957) legalized nonmedical cannabis. Participants reported descriptive THC:CBD ratios (e.g., high THC, low CBD) and numeric THC and CBD levels (mg or %) for products they usually use in each of nine product categories. Few consumers knew and were able to report the numeric THC or CBD levels of their usual cannabis products. For example, only 10% of dried herb consumers reported the THC level, approximately 30% of whom reported implausible values. A greater proportion of consumers reported a descriptive THC:CBD ratio of their usual product, ranging from 50.9% of edible users to 78.2% of orally ingested oil users. Consumers were substantially more likely to report products high in THC versus low in THC for all products except topicals and tinctures, whereas similar proportions reported using products high and low in CBD. Despite some evidence of greater knowledge in legal jurisdictions, knowledge was still low in states with legal cannabis markets. Consumer knowledge of THC and CBD levels was low, with only modest differences between consumers living in jurisdictions that had and had not legalized nonmedical cannabis. The findings cast doubt on the validity of self-reported cannabinoid levels.

摘要

本研究旨在调查消费者对常见大麻产品中四氢大麻酚(THC)和大麻二酚(CBD)含量的了解情况。数据来自于2018年8月至9月在线开展的国际大麻政策研究。受访者包括6471名过去12个月内使用过大麻的用户,年龄在16至65岁之间,通过非概率抽样方法从尼尔森全球消费者洞察小组招募而来。受访者来自加拿大(尚未将非医用大麻合法化,n = 2354)以及美国已将非医用大麻合法化(n = 2160)和未合法化(n = 1957)的州。参与者报告了他们通常使用的九种产品类别中每种产品的THC:CBD描述性比例(例如,高THC、低CBD)以及THC和CBD的具体含量(毫克或百分比)。很少有消费者知道并能够报告他们常用大麻产品的THC或CBD具体含量。例如,只有10%的干草药消费者报告了THC含量,其中约30%报告的值不合理。更大比例的消费者报告了他们常用产品的THC:CBD描述性比例,范围从食用产品用户的50.9%到口服油类产品用户的78.2%。除了外用产品和酊剂外,消费者报告使用高THC产品的可能性显著高于低THC产品,而报告使用高CBD和低CBD产品的比例相近。尽管有证据表明在大麻合法化的司法管辖区消费者了解程度更高,但在有合法大麻市场的州,了解程度仍然较低。消费者对THC和CBD含量的了解程度较低,生活在非医用大麻已合法化和未合法化司法管辖区的消费者之间差异不大。这些发现对自我报告的大麻素含量的有效性提出了质疑。

相似文献

1
Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.
Cannabis Cannabinoid Res. 2022 Jun;7(3):345-354. doi: 10.1089/can.2020.0092. Epub 2020 Oct 29.
3
Cannabinoid Exposure and Subjective Effects of THC and CBD in Edible Cannabis Products.
Cannabis Cannabinoid Res. 2024 Feb;9(1):320-334. doi: 10.1089/can.2022.0020. Epub 2022 Nov 15.
4
An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina.
Forensic Sci Int. 2023 Aug;349:111762. doi: 10.1016/j.forsciint.2023.111762. Epub 2023 Jun 22.
5
Self-reported THC content and associations with perceptions of feeling high among cannabis consumers.
Drug Alcohol Rev. 2023 Jul;42(5):1142-1152. doi: 10.1111/dar.13664. Epub 2023 Apr 16.
8
Re-Examining Cannabidiol: Conversion to Tetrahydrocannabinol Using Only Heat.
Cannabis Cannabinoid Res. 2024 Apr;9(2):486-494. doi: 10.1089/can.2022.0235. Epub 2022 Dec 13.
10
Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores.
JAMA Netw Open. 2022 Jul 1;5(7):e2223019. doi: 10.1001/jamanetworkopen.2022.23019.

引用本文的文献

2
Prevalence of cannabidiol use and correlates in U.S. adults.
Drug Alcohol Depend Rep. 2024 Oct 9;13:100289. doi: 10.1016/j.dadr.2024.100289. eCollection 2024 Dec.
5
Evolution of the substance use landscape: Implications for contingency management.
J Appl Behav Anal. 2025 Jan;58(1):36-55. doi: 10.1002/jaba.2911. Epub 2024 Aug 28.
6
Tobacco-cannabis co-use among cancer patients and survivors: findings from 2 US cancer centers.
J Natl Cancer Inst Monogr. 2024 Aug 15;2024(66):234-243. doi: 10.1093/jncimonographs/lgad035.
10
Knowledge of Cannabinoid Content Among People Living with HIV Who Use Cannabis: a Daily Diary Study.
Int J Behav Med. 2025 Apr;32(2):276-287. doi: 10.1007/s12529-023-10221-x. Epub 2023 Oct 4.

本文引用的文献

2
Availability, retail price and potency of legal and illegal cannabis in Canada after recreational cannabis legalisation.
Drug Alcohol Rev. 2020 May;39(4):337-346. doi: 10.1111/dar.13069. Epub 2020 Apr 14.
3
Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.
Lancet Psychiatry. 2020 Apr;7(4):344-353. doi: 10.1016/S2215-0366(20)30074-2. Epub 2020 Mar 17.
4
Cannabis labelling and consumer understanding of THC levels and serving sizes.
Drug Alcohol Depend. 2020 Mar 1;208:107843. doi: 10.1016/j.drugalcdep.2020.107843. Epub 2020 Feb 7.
5
Cannabidiol Products Are Everywhere, but Should People Be Using Them?
JAMA. 2019 Dec 10;322(22):2156-2158. doi: 10.1001/jama.2019.17361.
7
New trends in cannabis potency in USA and Europe during the last decade (2008-2017).
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):5-15. doi: 10.1007/s00406-019-00983-5. Epub 2019 Jan 22.
8
Chemometric Analysis of Cannabinoids: Chemotaxonomy and Domestication Syndrome.
Sci Rep. 2018 Aug 30;8(1):13090. doi: 10.1038/s41598-018-31120-2.
9
Big data on a big new market: Insights from Washington State's legal cannabis market.
Int J Drug Policy. 2018 Jul;57:86-94. doi: 10.1016/j.drugpo.2018.03.031. Epub 2018 Apr 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验